BRPI0820406A2 - Métodos para identificar aumento de antagonistas do receptor nmda - Google Patents

Métodos para identificar aumento de antagonistas do receptor nmda

Info

Publication number
BRPI0820406A2
BRPI0820406A2 BRPI0820406-3A BRPI0820406A BRPI0820406A2 BR PI0820406 A2 BRPI0820406 A2 BR PI0820406A2 BR PI0820406 A BRPI0820406 A BR PI0820406A BR PI0820406 A2 BRPI0820406 A2 BR PI0820406A2
Authority
BR
Brazil
Prior art keywords
methods
receptor antagonists
nmda receptor
identify increased
increased nmda
Prior art date
Application number
BRPI0820406-3A
Other languages
English (en)
Inventor
Raymond J Dingledine
Stephen F Traynelis
Dennis C Liotta
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BRPI0820406A2 publication Critical patent/BRPI0820406A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0820406-3A 2007-11-06 2008-11-06 Métodos para identificar aumento de antagonistas do receptor nmda BRPI0820406A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98592207P 2007-11-06 2007-11-06
US98592407P 2007-11-06 2007-11-06
PCT/US2008/082660 WO2009061935A2 (en) 2007-11-06 2008-11-06 Methods of identifying safe nmda receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0820406A2 true BRPI0820406A2 (pt) 2015-05-19

Family

ID=40626437

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820406-3A BRPI0820406A2 (pt) 2007-11-06 2008-11-06 Métodos para identificar aumento de antagonistas do receptor nmda

Country Status (12)

Country Link
EP (1) EP2212694A4 (pt)
JP (1) JP2011503013A (pt)
KR (1) KR20100100858A (pt)
CN (1) CN101918832A (pt)
AU (1) AU2008323877A1 (pt)
BR (1) BRPI0820406A2 (pt)
CA (1) CA2704475A1 (pt)
EA (1) EA201070571A1 (pt)
IL (1) IL205432A0 (pt)
MX (1) MX2010004971A (pt)
WO (1) WO2009061935A2 (pt)
ZA (1) ZA201003724B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159960A (ja) * 2011-06-08 2014-09-04 Astellas Pharma Inc 慢性疼痛モデル動物における自発痛行動自動測定法
DK3297619T3 (da) * 2015-05-22 2022-08-15 Vistagen Therapeutics Inc Terapeutiske anvendelser af L-4-chlorkynurenin
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
CN111960514A (zh) * 2020-08-28 2020-11-20 浙江浙能技术研究院有限公司 一种用于脱硫废水浓缩的电渗析智能控制系统及方法
JP2024533182A (ja) 2021-09-02 2024-09-12 エモリー ユニバーシティー 酸性pHで増強された効力を有するN-メチル-D-アスパラギン酸受容体のGluN2Bサブユニット選択的アンタゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー ユニバーシティ pHに依存するNMDAレセプターアンタゴニスト
KR20030063765A (ko) * 2002-01-24 2003-07-31 엘지전자 주식회사 광픽업용 대물렌즈
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2005061536A1 (en) * 2003-12-16 2005-07-07 Aventis Pharmaceuticals Inc. Secreted neural apoptosis inhibiting proteins
JP5015779B2 (ja) * 2004-08-23 2012-08-29 エモリー・ユニバーシテイ インビボ治療のためのpH依存性化合物の改良選択法

Also Published As

Publication number Publication date
EP2212694A4 (en) 2011-10-12
EP2212694A2 (en) 2010-08-04
WO2009061935A3 (en) 2009-08-20
ZA201003724B (en) 2013-10-30
CN101918832A (zh) 2010-12-15
WO2009061935A2 (en) 2009-05-14
IL205432A0 (en) 2010-12-30
CA2704475A1 (en) 2009-05-14
MX2010004971A (es) 2010-07-28
JP2011503013A (ja) 2011-01-27
EA201070571A1 (ru) 2010-12-30
AU2008323877A1 (en) 2009-05-14
KR20100100858A (ko) 2010-09-15

Similar Documents

Publication Publication Date Title
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
EP2150167A4 (en) SEMI-DISPOSABLE ENDOSCOPE
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
EP2350060A4 (en) Melanocortin receptor AGONISTS
EP1981902A4 (en) NOGO RECEPTOR ANTAGONISTS
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
HUE056626T2 (hu) Antitestkészítmény
BRPI0910592A2 (pt) antagonistas de receptor 2 de somatostatina
BRPI0810926A2 (pt) Antagonista de crig
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
BRPI0920440A2 (pt) preparação de alimentação de alquiliação
EP2490709A4 (en) PEPTIDIC GLP-2 AGONISTS
BRPI0811509A2 (pt) Mouse
EP2169075A4 (en) PREPARATION FOR ALKALOID
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
BRPI0918004A2 (pt) antagonistas de glucagon
HUE037394T2 (hu) Clever-1 receptor antagonisták immun-gátló 2 típusú makrofágok blokkolására

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.